Compound corresponding to the general formula (I):in which R2represents a hydrogen or fluorine atom or a hydroxyl, cyano,trifluoromethyl, C1-6-alkyl, C1-6-alkoxy or NR8R9group； n represents an integer equal to 1, 2 or 3 and m represents an integer equal to 1 or 2； A represents a covalent bond or a group C1-8-alkylene； R1represents a phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, naphthyl, quinolinyl, isoquinolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, cinnolinyl or naphthyridinyl group, this group being optionally substituted； R3represents a hydrogen or fluorine atom, a group C1-6-alkyl or a trifluoromethyl group； R4represents a group chosen from furyl, pyrrolyl, thienyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, imidazole, triazolyl, tetrazolyl, oxazolone, oxazolidinone, isoxazolone, isoxazolidinone, isothiazolone, isothiazolidinone, imidazolone, imidazolidinone, pyrazolone, pyrazolidinone, oxadiazolone, thiadiazolone and triazolone, this group being optionally substituted； in the form of base or of an acid-addition salt.Therapeutic use.本發明係關於對應於通式(I)之化合物：其中R2代表氫或氟原子或羥基、氰基、三氟甲基、C1-6-烷基、C1-6-烷氧基或NR8R9基團；n代表等於1、2或3之整數，m代表等於1或2之整數；A代表共價鍵或基團C1-8-伸烷基；R1代表苯基、吡啶基、嗒嗪基、嘧啶基、吡嗪基、三嗪基、萘基、喹啉基、異喹啉基、呔嗪基、喹唑啉基、喹喏啉基、啉基或啶基，該基團視情況經取代；R3代表氫或氟原子、基團C1-6-烷基或三氟甲基；R4代表選自以下之基團：呋喃基、吡咯基、噻吩基、異噻唑基、噁唑基、異噁唑基、吡唑基、噁二唑基、噻二唑基、咪唑基、三唑基、四唑基、噁唑酮、噁唑啶酮、異噁唑酮、異噁唑啶酮、異噻唑酮、異噻唑啶酮、咪唑酮、咪唑啶酮、吡唑啉酮、吡唑啶酮、噁二唑啉酮、噻二唑啉酮及三唑酮，該基團視情況經取代；該化合物呈鹼形式或酸加成鹽形式。治療用途。
